Emcure Pharmaceuticals Limited Beat Revenue Forecasts By 6.4%: Here's What Analysts Are Forecasting Next

The investors in Emcure Pharmaceuticals Limited's (NSE:EMCURE) will be rubbing their hands together with glee today, after the share price leapt 20% to ₹2,245 in the week following its quarterly results. Results overall were respectable, with statutory earnings of ₹48.77 per share roughly in line with what the analysts had forecast. Revenues of ₹28b came in 6.4% ahead of analyst predictions. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Following the latest results, Emcure Pharmaceuticals' eight analysts are now forecasting revenues of ₹110.8b in 2027. This would be a decent 8.3% improvement in revenue compared to the last 12 months. Per-share earnings are expected to step up 15% to ₹66.23. Before this earnings report, the analysts had been forecasting revenues of ₹106.1b and earnings per share (EPS) of ₹62.72 in 2027. So there seems to have been a moderate uplift in sentiment following the latest results, given the upgrades to both revenue and earnings per share forecasts for next year.

See our latest analysis for Emcure Pharmaceuticals

Despite these upgrades,the analysts have not made any major changes to their price target of ₹2,252, suggesting that the higher estimates are not likely to have a long term impact on what the stock is worth. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Emcure Pharmaceuticals, with the most bullish analyst valuing it at ₹2,500 and the most bearish at ₹1,900 per share. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We can infer from the latest estimates that forecasts expect a continuation of Emcure Pharmaceuticals'historical trends, as the 17% annualised revenue growth to the end of 2027 is roughly in line with the 16% annual growth over the past three years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 12% per year. So it's pretty clear that Emcure Pharmaceuticals is forecast to grow substantially faster than its industry.

The Bottom Line

The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Emcure Pharmaceuticals' earnings potential next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Emcure Pharmaceuticals analysts - going out to 2029, and you can see them free on our platform here.

It might also be worth considering whether Emcure Pharmaceuticals' debt load is appropriate, using our debt analysis tools on the Simply Wall St platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.